Overview

Evaluation of the Use of Granulocyte Colony Stimulating Factor (GCSF) in Post Kasai Type 3 Biliary Atresia

Status:
RECRUITING
Trial end date:
2026-10-30
Target enrollment:
Participant gender:
Summary
The aim of the study is to evaluate the use of Granulocyte Colony Stimulating Factor (GCSF) on the clinical and biochemical outcome of type 3 biliary atresia post kasai.
Phase:
NA
Details
Lead Sponsor:
National Liver Institute, Egypt
Treatments:
Granulocyte Colony-Stimulating Factor